AVROBIO Inc Stock

$25.40

5.46% yesterday

Nasdaq, Aug 21, 10:00 pm CET

ISIN

US05455M1009

Symbol

TECX

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

AVROBIO Inc Stock price

$25.40

-180.53 87.67% 5Y

Nasdaq, Closing price Thu, Aug 21 2025

+1.32 5.46%

ISIN

US05455M1009

Symbol

TECX

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Key metrics

Basic

Market capitalization

$450.6m

Enterprise Value

$163.9m

Net debt

positive

Cash

$287.4m

Shares outstanding

18.7m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

- | -

EV/Sales

- | -

EV/FCF

negative

P/B

1.6

Financial Health

Equity Ratio

92.1%

Return on Equity

-41.2%

ROCE

-26.2%

ROIC

Debt/Equity

0.0

Financials (TTM | estimate)

Revenue

$0.0 | $0.0

EBITDA

$-73.1m | $-80.6m

EBIT

$-74.3m | $-81.3m

Net Income

$-66.0m | $-77.8m

Free Cash Flow

$-64.4m

EPS

$-3.5

FCF per Share

$-3.4

Short interest

20.4%

Employees

Rev per Employee

As a Free StocksGuide user, you can view scores for all 7,014 stocks worldwide.

Get Started for Free Today

AVROBIO Inc Stock Analysis

Unlock Scores for Free

??

14 Analysts have issued a AVROBIO Inc forecast:

13x Buy

93%

More details on Analyst Estimates Including Price Targets

14 Analysts have issued a AVROBIO Inc forecast:

Buy

93%

Hold

Analyst Estimates with Stock Price Targets

Financial data from AVROBIO Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Jun '25		+/- %
Revenue	- -	- 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	21 21	14% 14% -
- Research and Development Expense	53 53	44% 44% -
EBITDA	-73 -73	29% 29% -
- Depreciation and Amortization	1.20 1.20	126% 126% -
EBIT (Operating Income) EBIT	-74 -74	30% 30% -
Net Profit	-66 -66	13% 13% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

AVROBIO Inc Stock News

Positive

The Motley Fool

●

14 days ago

Tectonic (TECX) Q2 R&D Soars 142%

Tectonic Therapeutic (TECX -5.35%), a biotechnology company advancing a new generation of biologic medicines for hard-to-treat diseases, reported its second quarter 2025 results on August 7, 2025. The headline news was a net loss (GAAP) of $20.0 million in Q2 2025, with a loss per share of $(1.07) (GAAP), wider than analysts' expectations of $(0.98) (GAAP).

Neutral

GlobeNewsWire

●

about 2 months ago

Tectonic Therapeutic Joins Russell 3000® Index

WATERTOWN, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced that it has been added to the broad-market Russell 3000® Index. Tectonic's addition fol...

Neutral

GlobeNewsWire

●

3 months ago

Tectonic Therapeutic Presents Complete Results for Positive Phase 1b Clinical Trial of TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF in Late-Breaking Presentation at ESC Heart Failure 2025

WATERTOWN, Mass., May 17, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”) today announced the complete results from Part A of the Phase 1b clinical trial of TX45 in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction (“PH-HFpEF”), which are being presented in a late-breaking, oral session at the European Society of Cardi...

More AVROBIO Inc News

Company Profile

Avrobio, Inc. engages in the development of lentiviral-based gene therapies. It focuses on developing potentially curative ex vivo lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. The firms clinical-stage programs include Fabry disease, Gaucher disease and cystinosis . The company was founded by Geoff Mackay in 2015 and is headquartered in Cambridge, MA.

Head office	United States
CEO	Alise Reicin
Founded	2015
Website	tectonictx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now